aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
© aVenture Investment Company, 2025. All rights reserved.
44 Tehama St, San Francisco, CA 94105
Privacy Policy
aVenture Investment Company ("aVenture") is an independent venture capital research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals.
While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision.
aVenture does not offer investment advisory services and is not registered as an investment adviser. The data provided by aVenture does not constitute recommendations or advice, whether by methodology or a statement written by a staff member of aVenture.
Links to external websites do not imply endorsement or affiliation with aVenture. References or links to providers offering the ability to invest in a primary or secondary transaction in a company are for convenience purposes only. They are not solicitations or offers to buy or sell an investment. Remember that past performance does not guarantee future results, and venture capital and private assets should be a contributory part of a diversified portfolio.
Lipella Pharmaceuticals is a Pittsburgh-based biotechnology company focused on developing and commercializing intravesical therapy products. Their core mission is to empower cancer survivorship and target serious and rare diseases through innovative drug delivery technology. They specialize in treatments for diseases affecting mucosal tissues.
Key achievements include expanding their clinical pipeline and advancing proprietary drug delivery systems. Led by CEO Dr. Jonathan Kaufman, Lipella has made significant strides in addressing unmet medical needs, impacting patient care and treatment outcomes.
Operating Status
Active
Ownership Type(s)
Venture Capital, Private
Main Product(s)
Biotech Products
Technology
Biotech
Model Types
Software
Revenue Type(s)
Recurring
Customer Type(s)
Enterprise
Geographic Exposure
United States
When was Lipella Pharmaceuticals founded?
Lipella Pharmaceuticals was founded in 2005.
Where is Lipella Pharmaceuticals's headquarters located?
Lipella Pharmaceuticals's headquarters is located in Pittsburgh, PA, US.
When was Lipella Pharmaceuticals's last funding round?
Lipella Pharmaceuticals's most recent funding round was for $2M (USD) in October 2023.
How many employees does Lipella Pharmaceuticals have?
Lipella Pharmaceuticals has 5 employees as of Feb 5, 2024.
How much has Lipella Pharmaceuticals raised to-date?
As of July 05, 2023, Lipella Pharmaceuticals has raised a total of $6.6M (USD) since Oct 23, 2023.
Add Comparison
Total Raised to Date
$6.6M
USD
Last Update Oct 23, 2023
Last Deal Details
$2M
USD
Oct 23, 2023
Post Ipo Equity
Total Employees Over Time
5
As of Feb 2024
Lipella Pharmaceuticals Address
400 N Lexington St
# 103
Pittsburgh,
Pennsylvania
15208
United States
Source(s): This page includes data and analysis provided by the company, OpenAI, and our research analysts